VICTORIA, BC, March 15, 2019 /CNW/ – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (TSX:IPA)(OTC:IPATF)(FRA: TQB2) today announces that Jos Raats, Ph.D., has resigned from the position of Managing Director of ModiQuest Research B.V. in order to pursue his duties as CEO of Absano BV, a company developing antibodies for therapeutic and diagnostic applications in the field of cancer, autoimmunity, and infection, along with TACPA B.V., a clinical stage company focusing on a phase I anti-inflammatory antibody candidate directed at multiple diseases, and which was developed using ModiQuest’s antibody technologies.
Dr. Raats was the founder of ModiQuest Research in 2005 and served as the Company’s Chief Executive Officer.
Also, effective March 15th, Debby Kruijsen, Ph.D., will begin serving as the General Manager of ModiQuest Research B.V. In 2012, Debby joined ModiQuest Research as a scientist supervising hybridoma antibody discovery projects. In 2013 Debby was appointed as Head Contract Research of ModiQuest Research where she was responsible for all contract research projects and is a member of the business development group.
“On behalf of the Company, I want to thank Jos for his valuable service and leadership,” said Jennifer Bath, ImmunoPrecise’s President and Chief Executive Officer. “He was instrumental in integration of ModiQuest Research into the IPA family of companies, and we wish him well in his future endeavors.”
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. (TSX:IPA)(OTC:IPATF)(FRA: TQB2) is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.
The services offered to clients include antibody discovery against a broad spectrum of antigens, including challenging targets. Amongst these services, the Company offers hybridoma production, B-cell services, and a variety of phage display platforms. The Company also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the fiscal year ended April 30, 2018 which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.
